Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 1997

View Archived Issues

Cortecs: fiscal 1997 highlights

Clinical pharmacokinetics and safety described for YM-90K

Clinical pharmacokinetic profile of rhIL-10

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Potential early warning sign for heart transplant rejection

Cell Genesys reports development of second-generation lentiviral gene delivery system

FDA approves irbesartan for marketing

SB-207499: a second-generation PDE IV inhibitor from SmithKline Beecham

New discovery enhances feasibility of cardiovascular gene therapy

Hoechst describes Na+/H+-exchange inhibitors for ischemic disorders

Key cardiovascular gene therapy patent awarded to CardioGene Therapeutics

Agents for postmenopausal syndrome in development at Lilly

Antihyperlipidemic/antidiabetic agents reported by Otsuka

A-74259, an alpha-glucosidase inhibitor isolated from Streptomyces

Genetic basis of asthma becoming clearer, researchers report

New antiarrhythmics from American Cyanamid

Aastrom Biosciences awarded two NIH grants; begins phase I trial of UCB transplants

Breast cancer imaging agent approved in Canada

First approval for Infergen

ImmunoCyt introduced in Canada and Europe

Geref cleared for pediatric growth disorders in U.S.

GenVec/Parke-Davis collaboration focusing on angiogenic products

Idoxifene progresses to phase III for osteoporosis

Dermagraft launched in the U.K.

PowderJect and Boehringer Mannheim agreement for protein delivery

Synthelabo acquires German generics company

FDA grant awarded for research on Dupuytren's disease therapy

NIH evaluates St. John's wort for depression

Novel amphotericin B formulation reported by Japanese academics

FDA panel recommends approval of new uterine thermal ablation system

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...